Vor Biopharma
Filed with the SEC on · accession 0001193125-26-439975
VOR filed a 424B5 (prospectus (offering)) with the SEC on Oct 30, 2026. The final terms of an offering of shares or bonds. The stock moved -5.9% by the first close after the filing.
Vor Biopharma entered into a new at-the-market sales agreement with William Blair and RBC Capital Markets to sell up to $150 million of common stock, replacing an expired prior sales agreement under which $125 million had been sold.
Close before
$20.91
Oct 29, 2026
First close after
-5.88%
$19.68
5 trading days
-10.76%
$18.66
Since filing
-4.93%
$19.88
✦ Ask GOAX AI about this filing — what it means for VOR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for VOR?
Click hereVOR filed a 424B5 (Shelf registration). Vor Biopharma entered into a new at-the-market sales agreement with William Blair and RBC Capital Markets to sell up to $150 million of common stock, replacing an expired prior sales agreement under which $125 million had been sold.
New shares dilute existing holders and are often sold at a discount to the market price.
The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.
VOR closed at $20.91 before the filing and $19.68 on Oct 30, 2026 (-5.88%). Five trading days later: $18.66 (-10.76%).
Get alerts when VOR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days